Functional Study to Investigate the Efficacy of a New Medical Device (Modified Diprobase Formulation)

Inclusion Criteria: * Patients being willing and able to provide written informed consent to participate in the study; * Patients with self-reported history of AD (at least one flare up in the past with mild to moderate intensity), but with no flare-up within the last month; * Patients aged between 18 - 65 years; * Corneometer value \< 35 a.u (on one volar forearm); * Skin type I-IV (Fitzpatrick et al. 1974); * Patients willing to adhere to trial procedures; * Patients willing to discontinue the use of own cleansing and cosmetic products (e.g. soaps, creams, moisturizers) in test areas 3 days before Day 1 and throughout the course of the trial; * Patients willing to stop smoking 2 hours before the instrumental measurements; * Patients willing not to drink caffeinated beverages 2 hours before the instrumental measurements; * Patients willing to avoid contact with water in the test areas 2 hours before the instrumental measurements; * Negative urine pregnancy test (for female patients of child bearing potential); * Women of child bearing potential have to use reliable methods of contraception with a low failure rate (i.e., less than 1 % per year; implants, injectables, combined oral contraceptives, hormone-based intrauterine-devices, sexual abstinence or vasectomized partner). Exclusion Criteria: * Any other skin disease on the whole body that would interfere the clinical assessment in the opinion of the Investigator; * Intake of drugs interfering with the immune system (e.g. corticosteroids, immunosuppressive drugs and antihistamines) within 30 days before screening as well as during the trial (with exception of routine vaccinations); * Intrarectal or topical corticosteroids (in the test area) within 2 weeks before screening as well as during the trial; * Known allergies to any of the ingredients of the test product; * Any use of another topical emollient or other established treatment for atopic dermatitis in the test area; * Any other adjuvant therapy for atopic dermatitis (UV therapy, probiotics homeopathy etc.); * Patients with a Body Mass Index \> 30; * Diabetes mellitus; * Patients who use tanning beds regularly within the past 2 years; * Exposure of the test area to the sun; * Pregnant or lactating women; * Moles, tattoos, pigmentation or scars on the forearms that would influence the instrumental measurements; * Hairy skin on test areas; * Patients with psychiatric conditions that might limit the participation in the trial and/or that lead to the assumption that the ability to completely understand the consequences of consent is missing; * Patients with any history of drug addiction or alcoholism in the past 3 years; * Patients with expected poor compliance; * Patients, who are inmates of psychiatric wards, prison or state institutions; * Participation in a clinical trial with investigational medicinal products or medical devices within the last 30 days prior to the start of this trial; * Patients underlying any other restrictions due to the participation in other tests / at other test institutes; * Employees of the trial sites or of the Sponsor's company; * Patients that according to the opinion of the Investigator should not participate in the trial for any reason.